antitubercular agents

Summary

Summary: Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.

Top Publications

  1. ncbi Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    AIDS 21:335-41. 2007
  2. ncbi The challenge of new drug discovery for tuberculosis
    Anil Koul
    Department of Antimicrobial Research, Janssen Research and Development, Johnson and Johnson, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Nature 469:483-90. 2011
  3. pmc Rapid molecular detection of tuberculosis and rifampin resistance
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    N Engl J Med 363:1005-15. 2010
  4. pmc Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology
    Danica Helb
    Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey 07103, USA
    J Clin Microbiol 48:229-37. 2010
  5. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
  6. ncbi Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
    Francois Xavier Blanc
    Pneumology Unit, Internal Medicine Department, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    N Engl J Med 365:1471-81. 2011
  7. pmc Integration of antiretroviral therapy with tuberculosis treatment
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    N Engl J Med 365:1492-501. 2011
  8. ncbi Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
    Grant Theron
    Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 184:132-40. 2011
  9. ncbi Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis
    Neel R Gandhi
    Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA
    Lancet 375:1830-43. 2010
  10. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007

Research Grants

Detail Information

Publications321 found, 100 shown here

  1. ncbi Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    AIDS 21:335-41. 2007
    ..To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa...
  2. ncbi The challenge of new drug discovery for tuberculosis
    Anil Koul
    Department of Antimicrobial Research, Janssen Research and Development, Johnson and Johnson, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Nature 469:483-90. 2011
    ..In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients...
  3. pmc Rapid molecular detection of tuberculosis and rifampin resistance
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    N Engl J Med 363:1005-15. 2010
    ..Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect...
  4. pmc Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology
    Danica Helb
    Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey 07103, USA
    J Clin Microbiol 48:229-37. 2010
    ..2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h...
  5. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
    ....
  6. ncbi Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
    Francois Xavier Blanc
    Pneumology Unit, Internal Medicine Department, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    N Engl J Med 365:1471-81. 2011
    ..Robust data are lacking with regard to the timing for the initiation of antiretroviral therapy (ART) in relation to the start of antituberculosis therapy...
  7. pmc Integration of antiretroviral therapy with tuberculosis treatment
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    N Engl J Med 365:1492-501. 2011
    ..We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains unresolved...
  8. ncbi Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
    Grant Theron
    Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 184:132-40. 2011
    ..Xpert MTB/RIF is a novel automated molecular diagnostic recently endorsed by the World Health Organization. However, performance-related data from high HIV prevalence settings are limited...
  9. ncbi Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis
    Neel R Gandhi
    Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA
    Lancet 375:1830-43. 2010
    ....
  10. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
    ..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence...
  11. ncbi The population dynamics and control of tuberculosis
    Christopher Dye
    World Health Organization, CH1211 Geneva 27, Switzerland
    Science 328:856-61. 2010
    ..Whatever the technology used, success depends critically on the social, institutional, and epidemiological context in which it is applied...
  12. ncbi Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
    Abigail Wright
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 373:1861-73. 2009
    ..The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide...
  13. ncbi American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis
    Henry M Blumberg
    Am J Respir Crit Care Med 167:603-62. 2003
  14. pmc Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study
    Bernard N Muture
    National Public Health Laboratory Services, Ministry of Health, PO Box 20750 00202, Nairobi, Kenya
    BMC Public Health 11:696. 2011
    ..Kenya is among countries with high tuberculosis burden globally. The purpose of this study was to determine the duration tuberculosis patients stay in treatment before defaulting and factors associated with default in Nairobi...
  15. pmc Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients
    Shama D Ahuja
    Bureau of Tuberculosis, New York, New York, United States of America
    PLoS Med 9:e1001300. 2012
    ..We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB...
  16. ncbi The HIV-associated tuberculosis epidemic--when will we act?
    Anthony D Harries
    International Union Against Tuberculosis and Lung Disease, Paris, France
    Lancet 375:1906-19. 2010
    ..The continuing HIV-associated tuberculosis epidemic needs bold but responsible action, without which the future will simply mirror the past...
  17. ncbi A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    Koen Andries
    Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium
    Science 307:223-7. 2005
    ..Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase...
  18. pmc Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010
    Matteo Zignol
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Bull World Health Organ 90:111-119D. 2012
    ..To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010...
  19. ncbi Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs
    Pedro Eduardo Almeida Almeida Da Silva
    Laboratory of Tuberculosis, Faculty of Medicine, Universidade Federal do Rio Grande FURG, Brazil
    J Antimicrob Chemother 66:1417-30. 2011
    ..tuberculosis...
  20. ncbi Mechanisms of drug resistance in Mycobacterium tuberculosis
    Y Zhang
    Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Int J Tuberc Lung Dis 13:1320-30. 2009
    ..Understanding the mechanisms of drug resistance in M. tuberculosis would enable the development of rapid molecular diagnostic tools and furnish possible insights into new drug development for the treatment of TB...
  21. ncbi WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
    D Falzon
    Stop TB Dept, World Health Organization, Geneva 27, Switzerland
    Eur Respir J 38:516-28. 2011
    ..Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens...
  22. ncbi Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
    Evan W Orenstein
    Tugela Ferry Care and Research Collaboration, Tugela Ferry, KwaZulu Natal, South Africa
    Lancet Infect Dis 9:153-61. 2009
    ..These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes...
  23. pmc The impact of diabetes on tuberculosis treatment outcomes: a systematic review
    Meghan A Baker
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    BMC Med 9:81. 2011
    ..We performed a systematic review and meta-analysis to quantitatively summarize evidence for the impact of diabetes on tuberculosis outcomes...
  24. ncbi Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
    Jose A Caminero
    Servicio de Neumologia, Hospital General de Gran Canaria, Las Palmas, Canary Islands, Spain
    Lancet Infect Dis 10:621-9. 2010
    ..Drugs in group five should be used in the following order: clofazimine, amoxicillin with clavulanate, linezolid, carbapenems, thioacetazone, then clarithromycin...
  25. pmc Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
    Payam Nahid
    Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
    BMC Infect Dis 11:1. 2011
    ..Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary tuberculosis under program settings...
  26. pmc SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis
    Kapil Tahlan
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 56:1797-809. 2012
    ..Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM...
  27. pmc Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis
    Patricia J Campbell
    Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 55:2032-41. 2011
    ..tuberculosis complex. Further, the results can be used to design diagnostic tests utilizing other mutation detection technologies...
  28. ncbi Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
    Robert S Wallis
    Pfizer, New London, CT, USA
    Lancet 375:1920-37. 2010
    ..Translation of scientific progress in biomarkers and diagnostics into clinical and public health programmes is possible-with political commitment, increased funding, and engagement of all stakeholders...
  29. pmc Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 8:516-23. 2008
    ..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
  30. pmc Paediatric tuberculosis
    Sandra M Newton
    Department of Paediatrics, Imperial College London, London, UK
    Lancet Infect Dis 8:498-510. 2008
    ..Advances in our understanding of tuberculosis in children would provide insights and opportunities to enhance efforts to control this disease...
  31. ncbi A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 405:962-6. 2000
    ..tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis...
  32. pmc Tuberculosis: what we don't know can, and does, hurt us
    David G Russell
    Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Science 328:852-6. 2010
    ..Here we focus on the biology of the host-pathogen interaction and discuss new and evolving strategies for intervention...
  33. pmc Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa
    James C M Brust
    Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America
    PLoS ONE 6:e15841. 2011
    ..We describe culture conversion rates among MDR-TB patients with and without HIV-co-infection in a TB-endemic, high-HIV prevalent, resource-limited setting...
  34. pmc Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis
    Lluis Ballell
    Tres Cantos Medicines Development Campus TCMDC, GlaxoSmithKline GSK, Severo Ochoa 2, Tres Cantos, Madrid, Spain
    ChemMedChem 8:313-21. 2013
    ..Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified...
  35. ncbi Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
    Tracy Dalton
    Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 380:1406-17. 2012
    ..We prospectively assessed resistance to second-line antituberculosis drugs in eight countries...
  36. ncbi Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
    Daphne Yee
    Respiratory Epidemiology Unit, Montreal Chest Institute, 1110 Pine Avenue West, Room 103, Montreal, PQ, H3A 1A3 Canada
    Am J Respir Crit Care Med 167:1472-7. 2003
    ..0; 95% CI, 1.5 to 43). The incidence of pyrazinamide-induced hepatotoxicity and rash during treatment for active TB was substantially higher than with the other first-line anti-TB drugs, and higher than previously recognized...
  37. pmc Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis
    Wei Lun Huang
    Reference Laboratory of Mycobacteriology, Research and Diagnostic Center, Centers for Disease Control, Taipei, Taiwan, Republic of China
    J Clin Microbiol 49:2502-8. 2011
    ..We recommend including new alleles consisting of the eis promoter and embB genes in molecular analysis. However, conventional DST is necessary to rule out false-negative results from molecular assays...
  38. ncbi Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries
    M A Espinal
    World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
    JAMA 283:2537-45. 2000
    ....
  39. pmc Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis
    Vadim Makarov
    A N Bakh Institute of Biochemistry, Russian Academy of Science, 119071 Moscow, Russia
    Science 324:801-4. 2009
    ..The most advanced compound, BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB...
  40. ncbi 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial
    Taraz Samandari
    Botswana USA Partnership BOTUSA, Gaborone and Francistown, Botswana
    Lancet 377:1588-98. 2011
    ..We aimed to assess effectiveness of extended isoniazid therapy...
  41. ncbi The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era
    B J Marais
    Centre for TB Research and Education, Stellenbosch University, Cape Town, Western Cape, South Africa
    Int J Tuberc Lung Dis 8:392-402. 2004
    ..Deciding which children to treat may be extremely difficult in high-prevalence, low-resource settings. The concept of relevant disease provides guidance for more effective public health intervention...
  42. ncbi An official ATS statement: hepatotoxicity of antituberculosis therapy
    Jussi J Saukkonen
    Am J Respir Crit Care Med 174:935-52. 2006
    ..Priorities for future studies to develop safer treatments for LTBI and for TB disease are presented...
  43. pmc The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study
    Ted Cohen
    Division of Global Health Equity, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000296. 2010
    ..We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis...
  44. pmc Comprehensive treatment of extensively drug-resistant tuberculosis
    Carole D Mitnick
    Harvard Medical School, Boston, USA
    N Engl J Med 359:563-74. 2008
    ..We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru...
  45. ncbi Facing the crisis: improving the diagnosis of tuberculosis in the HIV era
    Mark D Perkins
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    J Infect Dis 196:S15-27. 2007
    ..In this article, we will define the need for better TB tests and describe technologies being developed to meet that need...
  46. ncbi Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control
    Surendra K Sharma
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, All India Institute of Medical Sciences, New Delhi 110 029, India
    Chest 130:261-72. 2006
    ..With newer effective anti-TB drugs still a distant dream, innovative approaches such as DOTS-Plus are showing promise for the management of patients with MDR-TB under program conditions and appear to be a hope for future...
  47. ncbi Delamanid for multidrug-resistant pulmonary tuberculosis
    Maria Tarcela Gler
    Makati Medical Center, Manila, Philippines
    N Engl J Med 366:2151-60. 2012
    ....
  48. ncbi Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran
    Ali Akbar Velayati
    Mycobacteriology Research Centre, the National Research Institute of Tuberculosis and Lung Disease, World Health Organization Collaborating Centre, Shahid Beheshti University, Darabad, Tehran, Iran
    Chest 136:420-5. 2009
    ..The study documented the emergence of new forms of resistant bacilli (totally drug-resistant [TDR] or super extensively drug-resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB)...
  49. ncbi Challenges and opportunities in developing novel drugs for TB
    Takushi Kaneko
    TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005, USA
    Future Med Chem 3:1373-400. 2011
    ..In this perspective we will focus on the early discovery phases of drug development and try to provide snapshots of both the current status and future prospects...
  50. pmc Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis
    Joaquín Rullas
    GlaxoSmithKline, Infectious Diseases Centre of Excellence in Drug Discovery, Diseases of the Developing World, Madrid, Spain
    Antimicrob Agents Chemother 54:2262-4. 2010
    ..This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin...
  51. ncbi Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
    G Sotgiu
    Hygiene and Preventive Medicine Institute, University of Sassari, Sassari, Italy
    Eur Respir J 33:871-81. 2009
    ..Early diagnosis and aggressive management of extensively drug-resistant tuberculosis provide the best chance of positive outcome, but prevention is still paramount...
  52. ncbi New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis
    Justin O'Grady
    Department of Infection, University College London Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, London, UK
    Curr Opin Pulm Med 17:134-41. 2011
    ..During the past decade, there have been significant advances in diagnostic technologies for TB and drug-resistant TB. The purpose of this article is to review the current data, recommendations and evidence base for these tests...
  53. pmc High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv
    Robert C Reynolds
    Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
    Tuberculosis (Edinb) 92:72-83. 2012
    ....
  54. pmc Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  55. ncbi Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa
    Marinus Barnard
    Foundation for Innovative New Diagnostics, 71 av Louis Casai, 1216 Cointrin, Switzerland
    Am J Respir Crit Care Med 177:787-92. 2008
    ..Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings...
  56. ncbi Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view
    Carleitta Paige
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cell Microbiol 12:301-9. 2010
    ..Host-directed therapy that alters the immune response may offer an alternative approach towards reducing treatment duration, the risk of anti-microbial resistance and improving patient outcome...
  57. pmc Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates
    Laura E Via
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20852, USA
    Infect Immun 76:2333-40. 2008
    ..Thus, three independent lines of evidence support the hypothesis that hypoxic microenvironments are an important feature of some lesions in these animal models of tuberculosis...
  58. ncbi Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis
    Anil Koul
    Departments of Antimicrobial Research and Functional Genomics, Johnson and Johnson, Turnhoutseweg 30, B 2340 Beerse, Belgium
    J Biol Chem 283:25273-80. 2008
    ....
  59. pmc Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa
    Thomas R Ioerger
    Department of Computer Science and Engineering, Texas A and M University, College Station, Texas, United States of America
    PLoS ONE 4:e7778. 2009
    ....
  60. pmc High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv
    Subramaniam Ananthan
    Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
    Tuberculosis (Edinb) 89:334-53. 2009
    There is an urgent need for the discovery and development of new antitubercular agents that target new biochemical pathways and treat drug resistant forms of the disease...
  61. ncbi Mycobacterium tuberculosis: here today, and here tomorrow
    D G Russell
    Microbiology and Immunology, 5173 Veterinary Medical Center, Cornell University, Ithaca, New York 14853, USA
    Nat Rev Mol Cell Biol 2:569-77. 2001
    ..As the macrophage is key to clearing the infection, the interplay between the pathogen and its host cell reflects a constant battle for control...
  62. ncbi Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000
    T Santha
    Tuberculosis Research Centre, Chetput, Chennai, India
    Int J Tuberc Lung Dis 6:780-8. 2002
    ..To identify risk factors associated with default, failure and death among tuberculosis patients treated in a newly implemented DOTS programme in South India...
  63. pmc OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
    Makoto Matsumoto
    Microbiological Research Institute, Otsuka Pharmaceutical, Tokushima, Japan
    PLoS Med 3:e466. 2006
    ..Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment...
  64. ncbi International standards for tuberculosis care
    Philip C Hopewell
    Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Lancet Infect Dis 6:710-25. 2006
    ....
  65. ncbi Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis
    M Estee Torok
    Department of Infectious Diseases, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom
    Clin Infect Dis 52:1374-83. 2011
    ..The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown...
  66. ncbi Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis
    Woojin Lew
    Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
    Ann Intern Med 149:123-34. 2008
    ..Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility...
  67. ncbi Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis
    Susan E Dorman
    Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 180:273-80. 2009
    ..Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited...
  68. pmc Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis
    Wanliang Shi
    W Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    Science 333:1630-2. 2011
    ..Trans-translation is essential for freeing scarce ribosomes in nonreplicating organisms, and its inhibition may explain the ability of PZA to eradicate persisting organisms...
  69. pmc European union standards for tuberculosis care
    G B Migliori
    WHO Collaborating Centre for TB and Lung Diseases, Fondazione S Maugeri, Care and Research Institute, via Roncaccio 16, 21049 Tradate, Italy
    Eur Respir J 39:807-19. 2012
    ..These will support EU health programmes to identify and develop optimal procedures for TB care, control and elimination...
  70. ncbi Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru
    Carole Mitnick
    Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 348:119-28. 2003
    ..We evaluated the results of community-based therapy for multidrug-resistant tuberculosis in a poor section of Lima, Peru...
  71. pmc Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort
    Jonathan E Golub
    Johns Hopkins University, School of Medicine, 1550 Orleans St, 1M 07 Baltimore, MD 21231, USA
    AIDS 23:631-6. 2009
    ..There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa...
  72. pmc Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?
    S D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    Int J Tuberc Lung Dis 15:571-81. 2011
    ..Much earlier ART initiation with high coverage is required if ART is to substantially influence the incidence of TB...
  73. ncbi Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study
    Keertan Dheda
    Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, Cape Town, South Africa
    Lancet 375:1798-807. 2010
    ....
  74. ncbi IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection
    Annalisa Azzurri
    Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    Microbes Infect 7:1-8. 2005
    ..Active TB is associated with increased CXCL10 and PTX3 levels in the plasma. Although not specific for TB, measurement of these proteins may help the monitoring of disease activity and efficacy of therapy...
  75. ncbi HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers
    P Sonnenberg
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 358:1687-93. 2001
    ..We followed up a cohort of 326 South African mineworkers, who had successfully completed treatment for pulmonary tuberculosis in 1995, to determine the rate and mechanisms of recurrence...
  76. ncbi Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs
    Alimuddin Zumla
    University College London, Centre for Clinical Microbiology, Division of Infection and Immunity, London, UK
    J Infect Dis 205:S228-40. 2012
    ....
  77. ncbi Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis
    S Borrell
    Division of Mycobacterial Research, Medical Research Council National Institute for Medical Research, London, UK
    Int J Tuberc Lung Dis 13:1456-66. 2009
    ..Such increased knowledge will allow for better epidemiological predictions and assist in the development of new tools and strategies to fight drug-resistant TB...
  78. ncbi Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy
    Andrew Boulle
    School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    JAMA 300:530-9. 2008
    ..Rifampicin-based antitubercular therapy reduces the plasma concentrations of nevirapine and efavirenz. The virological consequences of these interactions are not well described...
  79. ncbi Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects
    Ekaterina V Kurbatova
    U S Centers for Disease Control and Prevention, International Research and Programs Branch, Division of Tuberculosis Elimination, Atlanta, GA 30333, USA
    Tuberculosis (Edinb) 92:397-403. 2012
    ..To prevent treatment default, management of patients who are unemployed, homeless, alcoholic, or have a prison history requires extra measures to insure treatment completion...
  80. ncbi Which new diagnostics for tuberculosis, and when?
    Frank Cobelens
    Department of Global Health, Academic Medical Center and Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands
    J Infect Dis 205:S191-8. 2012
    ..The evidence for both steps should be systematically collected, but each requires different study designs...
  81. pmc Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis
    Juan Carlos Palomino
    Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, Antwerp 2000, Belgium
    Antimicrob Agents Chemother 46:2720-2. 2002
    ..Specificity and sensitivity were excellent. The method is simple, inexpensive, and rapid and might be used with other antituberculosis drugs...
  82. ncbi The diarylquinoline TMC207 for multidrug-resistant tuberculosis
    Andreas H Diacon
    Centre for Clinical Tuberculosis Research, the Department of Science and Technology, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, all in South Africa
    N Engl J Med 360:2397-405. 2009
    ..TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis...
  83. pmc Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis
    Catherine Riou
    Division of Immunology, Institute of Infectious Diseases and Molecular Medicine IIDMM, Clinical Laboratory Sciences, University of Cape Town, Cape Town, Western Cape, South Africa
    PLoS ONE 7:e36886. 2012
    ..The goal of this study was to evaluate changes in plasma cytokines in patients undergoing treatment for TB as a means of identifying candidate host markers associated with microbiologic response to therapy...
  84. pmc Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening
    Sarah A Stanley
    The Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA
    ACS Chem Biol 7:1377-84. 2012
    ..This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored...
  85. ncbi Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis
    Faiz A Khan
    Montreal Chest Institute, McGill University Health Centre, Montreal, Canada
    Clin Infect Dis 50:1288-99. 2010
    ..Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse...
  86. ncbi Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis
    Pedro Eduardo Almeida da Silva
    Universidade Federal do Rio Grande, Rio Grande, BrazilMycobacteriology Unit, Institute of Tropical Medicine Antwerp, Belgium
    FEMS Immunol Med Microbiol 63:1-9. 2011
    ..tuberculosis. This minireview describes the current knowledge on drug efflux in M. tuberculosis...
  87. ncbi Leads for antitubercular compounds from kinase inhibitor library screens
    Sophie Magnet
    Global Health Institute, Ecole Polytechnique Federale de Lausanne, CH 1015 Lausanne, Switzerland
    Tuberculosis (Edinb) 90:354-60. 2010
    ..Like the BTZ, VI-9376 was shown to act on the essential enzyme decaprenylphosphoryl-β-D-ribose 2'-epimerase, DprE1, required for arabinan synthesis...
  88. ncbi Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment
    A Trajman
    Pró reitoria de Saúde, Gama Filho University, Brazil
    Int J Tuberc Lung Dis 14:551-9. 2010
    ..Randomised controlled trial of latent tuberculosis infection (LTBI) treatment in 10 clinics in Canada, Saudi Arabia and Brazil...
  89. pmc Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa
    N Sarita Shah
    Tugela Ferry Care and Research Collaboration, Tugela Ferry, South Africa
    Emerg Infect Dis 17:510-3. 2011
    ..Of 19 patients with extensively drug-resistant TB identified during February 2008-April 2009, 13 (68%) had isolates resistant to all 8 drugs tested. This resistance leaves no effective treatment with available drugs in South Africa...
  90. pmc Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China
    Penghui Shang
    Department of Epidemiology and Bio statistics, School of Public Health, Peking University Health Science Centre, Beijing, China
    PLoS ONE 6:e21836. 2011
    ..This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China...
  91. ncbi National survey of drug-resistant tuberculosis in China
    Yanlin Zhao
    Chinese Center for Disease Control and Prevention, and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
    N Engl J Med 366:2161-70. 2012
    ..The available information on the epidemic of drug-resistant tuberculosis in China is based on local or regional surveys. In 2007, we carried out a national survey of drug-resistant tuberculosis in China...
  92. pmc Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa
    Stephanus Komati
    South African National Defence Force, Pretoria, South Africa
    AIDS 24:1849-55. 2010
    ..To determine important risk factors for and impact of tuberculosis on survival in HIV-infected patients starting antiretroviral therapy (ART) in South Africa...
  93. ncbi Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004
    V Leimane
    State Agency of Tuberculosis and Lung Diseases, Riga, Latvia
    Eur Respir J 36:584-93. 2010
    ..Overall, treatment success among all MDR-TB cases increased over time. Strategies to prevent transmission of XDR-TB and to further improve treatment outcome are crucial for the future of TB control in Latvia...
  94. pmc PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release
    Ramandeep Singh
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Science 322:1392-5. 2008
    ..Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug. Thus, these compounds may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system...
  95. ncbi LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
    U Mack
    Lovisenberg Diakonale Sykehus, Oslo, Norway
    Eur Respir J 33:956-73. 2009
    ..In summary, the main issue regarding testing is to restrict it to those who are known to be at higher risk of developing tuberculosis and who are willing to accept preventive chemotherapy...
  96. ncbi Hepatotoxicity of pyrazinamide: cohort and case-control analyses
    Kwok C Chang
    Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong, China
    Am J Respir Crit Care Med 177:1391-6. 2008
    ..Relatively little is known about the hepatotoxicity of pyrazinamide...
  97. pmc Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis
    Montserrat Garrigó
    Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni M Claret, 167, 08025 Barcelona, Spain
    J Clin Microbiol 45:1766-70. 2007
    ..In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs...
  98. ncbi The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan
    C S Wang
    Dept of Internal Medicine, Kaohsiung Municipal Hsiao Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC
    Infection 36:335-40. 2008
    ..The aim of this study was to investigate the impact of age on the demographic, clinical, radiographic characteristics, and treatment outcomes of pulmonary TB patients in Taiwan...
  99. ncbi GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis
    D I Ling
    Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada
    Eur Respir J 32:1165-74. 2008
    ..While specificity is excellent for isoniazid, sensitivity estimates were modest and variable. Together with data from demonstration projects, the meta-analysis provides evidence for policy making and clinical practice...
  100. ncbi The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
    A Telenti
    Institute for Medical Microbiology, University of Bern, Switzerland
    Nat Med 3:567-70. 1997
    ..Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis...
  101. ncbi Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome
    Timothy H Holtz
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:650-9. 2006
    ....

Research Grants72

  1. BIOSYNTHESIS OF ANTITUBERCULAR NONRIBOSOMAL PEPTIDES
    T Zabriskie; Fiscal Year: 2006
    ..will yield valuable information that will be translated into novel molecular tools for generating new antitubercular agents. The knowledge and methods that arise from these studies will be directly applicable to expanding the ..
  2. A Fluorescence Polarization Assay for Fatty Acid Adenylating Enzymes
    Courtney C Aldrich; Fiscal Year: 2012
    ..of the FadD's play in lipid metabolism and could additionally lead to the development of new class of antitubercular agents. Toward this goal we propose to develop a fluorescence polarization assay amenable to high throughput ..
  3. Design of antituberculosis agents that target siderophore biosynthesis
    Courtney C Aldrich; Fiscal Year: 2013
    ..The proposed research is expected to validate siderophore biosynthesis as new antibacterial target, which may lead to the development of a new class of antitubercular agents.
  4. MECHANISM BASED INHIBITION OF M TUBERCULOSIS ENZYMES
    John S Blanchard; Fiscal Year: 2012
    ..With the emergence and spread of multi-drug resistant strains of the bacteria, new targets must be identified and developed to which new inhibitors can be identified, allowing new therapeutically useful drugs to be developed. ..
  5. ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
    Evan D Kharasch; Fiscal Year: 2012
    ..It is also relevant to creating a better basic understanding of how drugs enter the brain and are inactivated by the body, and how therapeutic drugs affect healthy and ill individuals. ..
  6. Gyrase B Inhibitors for Mycobacterium Tuberculosis
    Peter B Madrid; Fiscal Year: 2013
    ..The development of a shorter, more effective treatment regimen will increase patient compliance and thereby slow down the emergence of drug resistance and protect vulnerable populations worldwide. ..
  7. Advancing lead dipiperidine compound into preclinical development
    Marina Protopopova; Fiscal Year: 2009
    ..Completion of these Specific Aims will provide vital data in support of development of SQ609 as an antitubercular and a firm rationale for determining whether or not to advance SQ609 into the extensive preclinical testing. ..
  8. Targeting MDR-TB
    Robert C Reynolds; Fiscal Year: 2010
    ..be to bring data for a select set of compounds that have promise for new drug discovery into the public and commercial domain for further advancement towards new antitubercular agents to treat drug resistant disease.
  9. Low Cost Monitoring Strategy to Optimize Tuberculosis Treatment in Children
    Susan M Abdel-Rahman; Fiscal Year: 2012
    ..As a research tool, DBS technology will allow investigators to validate dose-exposure relationships in populations that would otherwise never be represented in pharmacokinetic studies. ..
  10. Porins of Mycobacterium tuberculosis
    Michael Niederweis; Fiscal Year: 2009
    ..These studies will not only be essential for the design of new TB drugs, but will also be of fundamental interest for our understanding of nutrient uptake by M. tuberculosis. ..
  11. AEROSOL FOR ANTITUBERCULAR DRUG DELIVERY
    Anthony Hickey; Fiscal Year: 1999
    ..Therapeutic targeting may be demonstrated by delivering microparticles containing antitubercular agents as aerosols to macrophages in the lungs of diseased animals and evaluating their action...
  12. Inhibitor of FtsZ Polymerization in M. tuberculosis
    Robert Reynolds; Fiscal Year: 2004
    DESCRIPTION (Provided by the applicant): Development of new antitubercular agents is of critical importance worldwide...
  13. RIFAMYCIN BIOSYNTHETIC ANALOGS
    Chaitan Khosla; Fiscal Year: 2003
    ..6) Engineer the rifamycin gene cluster for overproduction of rifamycin B and eventual rifamycin analogs. (7) If necessary, move some of the rifamycin gene cluster into Streptomyces lividans to facilitate aims 4 - 6. ..
  14. Specific target of NO-mediated damage in M tuberculosis
    Kyu Rhee; Fiscal Year: 2007
    ..tuberculosis offers the promise of developing novel antitubercular agents that augment or mimic the natural immune response to infection with M...
  15. Pseudopteroxazole and Related Antitubercular Agents
    Michael Harmata; Fiscal Year: 2007
    The goals of this work are to develop syntheses of antitubercular agents based on natural product leads...
  16. ESSENTIAL GENES OF THE MYCOBACTERIA
    Graham Hatfull; Fiscal Year: 1999
    ..Many of the essential genes identified will be potential targets for antimycobacterial agents and will serve as an initiation point for the rationale design of novel antitubercular drugs. ..
  17. Total Synthesis of Tubelactomicin A and Kijanolide
    TONY TRULLINGER; Fiscal Year: 2004
    ..Macrolactonization will afford the natural product. ..
  18. Thioesterase Inhibitors of Mycolic Acid Biosynthesis as Antitubercular Agents
    Courtney Aldrich; Fiscal Year: 2008
    ..Additionally, this strategy may be adapted to inhibit critical PKSs from other pathogenic microorganisms. [unreadable] [unreadable] [unreadable]..
  19. BCG + hsp, a New Tuberculosis Vaccine
    Boris Nikonenko; Fiscal Year: 2003
    ..We will also examine the antibiotic sensitivity of this rBCGdeltahspR to 10 commonly used TB drugs to ensure that the genetic manipulations performed have not made it less sensitive to drug treatment. ..
  20. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2002
    ....
  21. Rapid Detection of Mycobacterium tuberculosis
    Susan Dorman; Fiscal Year: 2007
    ..unreadable] [unreadable] Relevance: Results of these studies will improve our understanding of the laboratory performance and clinical benefit of this test, and lead to improved detection and treatment of TB. [unreadable] [unreadable]..
  22. Domoic Acid and Neonatal Microglia Activation
    Alejandro Mayer; Fiscal Year: 2004
    ..activated microglia cells and their mediators play in DOM-induced excitotoxic neuronal injury and thus contribute to potential novel approaches for the therapy of the neuropathology associated with Amnesic Shellfish Poisoning in humans ..
  23. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy R Sterling; Fiscal Year: 2010
    ..tuberculosis would clarify whether fluoroquinolones are indeed a viable option for the first-line treatment of tuberculosis, and how best to preserve their usefulness against tuberculosis. ..
  24. Epidemiology of multidrug-resistant tuberculosis in Peru
    Mercedes Becerra; Fiscal Year: 2008
    ..tuberculosis strains. Results will serve to guide basic research in tuberculosis diagnostics and therapeutics. ..
  25. Structure Function Analysis of TB Pyrazinamidase
    Ying Zhang; Fiscal Year: 2005
    ..These studies will provide important information about mechanisms of PZA action and resistance and may help design new antituberculosis drugs. ..
  26. Mycobacterium tuberculosis cell wall virulence factors
    Susan Dorman; Fiscal Year: 2004
    ..Finally, new information from the proposed self-contained pilot studies will serve as the foundation for future comprehensive dissection of macrophage response pathways affected by specific cell wall components. ..
  27. IRON REGULATION & VIRULENCE--MYCOBACTERIUM TUBERCULOSIS
    YUKARI MANABE; Fiscal Year: 2003
    ..Elucidation of this iron-dependent IdeR regulon may lead to the identification of virulence determinants, and novel antigens for vaccines and therapeutics. ..
  28. MACROPHAGES, DENDRITIC CELLS AND PATHOGENS
    Carl Nathan; Fiscal Year: 2007
    ..Cores provide for BSL3 wet lab and mouse work; microarray analysis of gene expression; computation and comparison of gene expression results; and high throughput screening of chemical libraries. ..
  29. Sample Processing Cartridges for Rapid PCR TB Detection
    David Alland; Fiscal Year: 2008
    ..The system will then be retested using a large number of clinical sputum specimens. Finally, we will develop complete documentation on the assay including production, and development reports. [unreadable] [unreadable] [unreadable]..
  30. Towards drugs that prevent resistance to the HIV OI, TB
    David Alland; Fiscal Year: 2006
    ..if embB306 mutations affect biosynthesis of LAM, capped LAM, arabinogalactan (AG) or other cell wall components in the presence and absence of EMB. ..
  31. Detection of Select Agents in Single-Well Assays
    David Alland; Fiscal Year: 2007
    ..3. To develop PCR assays that utilize "color-triplet coding" to uniquely label as many as 56 different species-specific molecular beacons. ..
  32. POPULATION BASED INVESTIGATIONS OF TUBERCULOSIS
    David Alland; Fiscal Year: 2004
    ..Studies of these sequence variations in clinical strains will be used to determine the associations between specific mutations and the phenotypes of infectivity and virulence. ..
  33. TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUM
    David Alland; Fiscal Year: 2005
    ..4) To identify and validate an informative set of SNPs for worldwide evolutionary and epidemiological analyses. ..
  34. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  35. Oxidative Stress and the Pathogenesis of Sarcopenia and Disability in Older Women
    Richard Semba; Fiscal Year: 2008
    ..AGEs are a potentially modifiable risk factor, as circulating AGEs can be lowered by dietary modification and by pharmacological intervention. ..
  36. Mouse Strain dependent innate resistance to intestinal amebiasis
    Eric Houpt; Fiscal Year: 2009
    ....
  37. COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTS
    Elinore McCance Katz; Fiscal Year: 2002
    ..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
  38. Disulfiram Interactions With HIV Medications: Clinical Implications
    Elinore F McCance Katz; Fiscal Year: 2010
    ....
  39. Clinical Trial of Short Course vs. INH for LTBI in Jail
    Mary White; Fiscal Year: 2008
    ..Analysis of completion of therapy and cost-effectiveness of this regimen will provide important information for policy change in the way LTBI is managed in jail. ..
  40. Hepcidin and the pathogenesis of anemia in older adults.
    Richard D Semba; Fiscal Year: 2010
    ..This study should provide new insight into the epidemiology and biological mechanisms of anemia among older adults and help identify strategies aimed at the prevention and treatment of anemia. ..
  41. Cell Biology of Mycobacterium tuberculosis Infection
    David G Russell; Fiscal Year: 2010
    ..tuberculosis. We propose determining how the bacterium's metabolism is realigned to access these carbon sources. ..
  42. Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV Coinfection
    Elinore F McCance Katz; Fiscal Year: 2011
    ..The proposed studies will inform clinical treatment of comorbid HIV/AIDS, Hepatitis C and alcohol use/abuse leading to improved clinical outcomes and reduced risk of HIV transmission. ..
  43. CATALASE-PEROXIDASE CATALYSIS IN ANTIBIOTIC ACTIVATION
    RICHARD MAGLIOZZO; Fiscal Year: 2002
    ..The results of the proposed studies will advance a detailed understanding of the action of a first line antibiotic in current use to treat tuberculosis. ..
  44. Regulated expression of B. burgdorferi virulence genes
    FELIPE CARDENAS CABELLO; Fiscal Year: 2010
    ..burgdorferi. These tools will be used to identify genes that are potentially responsible for this organism's virulence and which could be targets for new vaccines and antibiotics against Lyme disease. ..
  45. DRUGS AND DELIVERY SYSTEMS FOR OPPORTUNISTIC INFECTIONS
    Marvin Miller; Fiscal Year: 2002
    ....
  46. RECOMBINANT BCG MALARIA VACCINES
    William Jacobs; Fiscal Year: 2001
    ..The immunization studies are designed to test the recombinant BCG's expressing MSP-1 for protection and their abilities to induce a priming immunization that can confer protection upon infection with the malarial parasites. ..
  47. Improving Health Outcomes for Released HIV+ Prisoners
    Frederick Altice; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  48. Prevalence, risk factors and consequences of complex M. Tuberculosis infections
    Theodore Cohen; Fiscal Year: 2010
    ..The overall goal of this study is to learn more about the natural history of TB and to use this knowledge to improve the health of individuals and their communities. ..
  49. Genetic approaches to protein-protein interactions mediating antibiotic resistanc
    CHRISTOPHER KRISTICH; Fiscal Year: 2009
    ....
  50. Development of a Novel Strategy of Adjuvant Discovery
    David Russell; Fiscal Year: 2009
    ..It is anticipated that this final aim will develop into a new grant application that will enable us to test the effectiveness of a range of microbial products for their efficacy as adjuvants. ..
  51. The role of NK cells in human M. Tuberculosis infection
    Ramakrishna Vankayalapati; Fiscal Year: 2009
    ..These findings will facilitate development of immunomodulatory strategies to boost the immune response to M. tuberculosis, including multidrug-resistant tuberculosis. ..
  52. Mucosal immune regulation in murine amebic colitis
    Eric Houpt; Fiscal Year: 2007
    ..The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology. ..
  53. Zeiss LSM510 Meta Confocal Microscope
    David Russell; Fiscal Year: 2007
    ..These data will extend ongoing, NIH-funded programs for identification of new drug targets, vaccines and adjuvants. [unreadable] [unreadable] [unreadable]..
  54. MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS
    William Jacobs; Fiscal Year: 2003
    ..Ultimately, the knowledge of mycobacterial virulence and persistence factors should lead to the development of novel drugs, vaccines, and immunotherapies to control tuberculosis. ..
  55. Neurodevelopment and HIV/AIDS
    Annelies Van Rie; Fiscal Year: 2005
    ....
  56. Real-time PCR diagnostic kit for Giardia and Cryptosporidium
    Eric Houpt; Fiscal Year: 2006
    ..A Phase II application is anticipated to validate the final diagnostic test product against immunoassay for an FDA 501 (k) medical device application. [unreadable] [unreadable] [unreadable]..
  57. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  58. Bioactive Compounds from Acylnitroso Cycloadducts
    Marvin Miller; Fiscal Year: 2006
    ..abstract_text> ..
  59. Evaluation of MDR-TB Treatment Strategies in Lima, Peru
    Sonya Shin; Fiscal Year: 2006
    ..abstract_text> ..
  60. Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB
    Carole Mitnick; Fiscal Year: 2007
    ..Moreover, this trial will contribute to the existing evidence base about possible surrogate endpoints, thereby simplifying future trials of investigational new anti-tuberculosis [unreadable] [unreadable] [unreadable]..
  61. Multiplex bead-PCR diagnosis for AIDS diarrhea
    Eric Houpt; Fiscal Year: 2007
    ..Finally, syndrome-based multiplex diagnosis is the platform of the future for clinical microbiology, and if this assay works on stool it should work on sputum, blood, or spinal fluid. [unreadable] [unreadable] [unreadable]..
  62. Mathematically modeling the transmission and control of extensively drug resistan
    Sanjay Basu; Fiscal Year: 2008
    ..The goal of this project is to determine how to reduce XDR tuberculosis incidence, using mathematical models of its transmission. [unreadable] [unreadable] [unreadable]..
  63. Opioids & HIV Medications: Interactions in Drug Abusers
    Elinore McCance Katz; Fiscal Year: 2008
    ..Drug interaction studies of the type proposed have been identified as a priority research area for NIDA because of their importance to optimizing the clinical care of HIV disease in opioid dependent patients. ..
  64. Pulmonary Hypertension and the Hypoxic Response in SCD
    Victor Gordeuk; Fiscal Year: 2008
    ..Aim 3. Using micro array analysis and high throughput genotyping, examine patterns of gene expression and candidate gene polymorphisms of the HIF-mediated hypoxic response in SCD and CP patients with and without PHTN. ..
  65. COCAETHYLENE COCAINE AGONIST THERAPY/TOLERANCE INDUCTION
    Elinore McCance Katz; Fiscal Year: 2002
    ..Positive findings from these studies could be followed in future studies with clinical trials to assess the efficacy of this class of drugs in the treatment of cocaine dependence. ..
  66. INH-induced lysis of the HIV opportunistic infection, M. tuberculosis
    William Jacobs; Fiscal Year: 2008
    ..The knowledge gained by this work will lead to the identification of novel drug targets, strategies to overcome tolerance, and more effective treatments for tuberculosis. ..
  67. Training in Translational Lung Research
    Neil Schluger; Fiscal Year: 2008
    ..abstract_text> ..
  68. Molecular approaches for understanding TB dynamics
    Theodore Cohen; Fiscal Year: 2008
    ..It is our hope that better analytic techniques will allow for more accurate assessments of treatment and prevention. [unreadable] [unreadable]..
  69. ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS
    Richard Semba; Fiscal Year: 2005
    ....
  70. Howard-CNMC Sickle Cell Disease Clinical Center
    Victor Gordeuk; Fiscal Year: 2008
    ..A major feature of both sickle cell programs has always been continuity of care and participation in collaborative research. ..
  71. Metabolism of M. tuberculosis: New Targets for MDR TB
    David Russell; Fiscal Year: 2004
    ..abstract_text> ..